Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

Sacroiliac joint, biopsy of, histologic findings of, in AS, 499
Sacroiliac symptoms, lumbar, and sacroiliitis, in juvenile AS, 835
Sacroiliitis, pathogenesis of spondylarthropathies and, 1547
Saline
antiinflammatory mechanism of adenosine regulators and, 1040
synovitis, protein clearance and, 1085
Salivary endothelial cells, E-selectin in, in SSc, 406
Salivary gland
cognitive deficit in rheumatic diseases and, 1361
T cell receptor Vβ genes in, in MRL/lpr mice with Sjogren's syndrome, 1077
Salmonella, in pathogenesis of spondylarthropathies, 1547
Sandwich enzyme immunoassays, to study stromelysin-1 and TIMP-1 in RA, 969
Sandwich enzyme-linked immunosorbent assay, to study soluble Fas/APO-1/CD95 in SLE and JRA, 1735
San Mateo Arthritis Project Survey, access to medical care for musculoskeletal conditions and, 1128
Sarcoidosis, hand in, 1733
Satiety, in acute parvovirus B19-induced pancytopenia after MTX in RA, 1023
Scans
cognitive deficit in rheumatic diseases and, 1361
joint and connective tissue ultrasonography and, 736
Schur, Peter H., editor, Arthritis and Rheumatism, 1990-95, 743
Scintigraphy
abnormalities on, bone turnover and, in OA, 78
bone, 1025, 1506
joint and connective tissue ultrasonography and, 736
Sclerodactyly, diltiazem in calcinosis and, 1646
Scleroderma
See also systemic sclerosis
cognitive deficit in rheumatic diseases and, 1361
elastin and collagen degradation in, 517
guidelines for clinical trials in, 351
immunosuppressive drugs during pregnancy and, 1722
lung disease, 1345
Raynaud's phenomenon and, 1
silicone breast implants and, 719
soluble adhesion molecules and disease activity in, 184
in Tsk2 mouse, 1791
Second-line drugs, in RA, 318, 334, 1595
Secondary amyloidosis, nephrotic syndrome and, in RA, azathioprine and, 1851
Seizures
cognitive deficit in rheumatic diseases and, 1361
spin-spin relaxation of brain in SLE and, 810
Self-antigens
autoimmune disease induction by microbial pathogens and, 458
in RA, 477, 577
T cell receptor Vβ genes and, in MRL/lpr mice with Sjogren's syndrome, 1077
Self-assessment
draft guidelines for drugs in JRA clinical trials and, 715
functional disability in PM/DM and, 1219
racial factors in gout and, 628
self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) in epidemiology, 795
Self-efficacy, stress management in clinical outcomes in RA and, 1807
Self-epitopes
autoimmune disease induction by microbial pathogens and, 458
in pathogenesis of spondylarthropathies, 1547
Self-management, Arthritis Knowledge Questionnaire and, 590
Self molecules, in pathogenesis of spondylarthropathies, 1547
Semiquantitative hybridization, to study T cell receptors in RA, 1242
Sensory deficits and sensory neuropathies, peripheral neuropathy with necrotizing vasculitis in RA and, 1618
Sensory neuropeptides, substance P and calcitonin gene-related peptide in rat adjuvant arthritis, 699
Sentinel enteric infection, autoimmune disease induction by microbial pathogens and, 458
Sequence homology, DNA, anti-apolipoprotein A1 in SLE and, 1655
Sequence-specific oligonucleotides, shared-epitope DRB1 alleles, RA gene and, 1754
Sequence variation, polyglot, polymorphism and, 1715
Septic arthritis, risk factors for, in joint disease, 1819
Septic polyarthritis, Ureaplasma urealyticum destructive common variable immunodeficiency in, 1524
Septicemia, Staphylococcus aureus, spinal involvement in gout and, 139
Sequence analysis
DNA, to study stromelysin-cleaved rabbit aggrecan, 1400
to study Mi-2 autoantigen in DM and, 1389
to study T cell receptors in RA, 577
Sequential liver biopsy, after MTX in RA, 1194
Serial radiographs, diltiazem in calcinosis and, 1646
Serine protease, granzyme A, perforin mRNA and, in RA synovium, 477
Serology
in antineutrophil cytoplasmic antibodies in SLE, 633
in bone marrow transplantation in antiphospholipid syndrome, 115
in fatal pulmonary vasculitis in lupus pregnancy, 710
HLA antigens, disease progression and, in psoriatic arthritis, 845
HLA-B39 and, in AS and pauciarticular JRA , 1672
HLA-DR5 (DRB1*1201) in primary antiphospholipid syndrome in Mexican patients and, 1340
HLA-DR8, acute anterior uveitis and, in AS, 547
in Lyme arthritis in European children and adolescents, 361
in SSc, 985, 1845
Seronegative oligoarthropathy, undifferentiated, Chlamydia DNA in, 1005
Seronegative spondylarthropathies, HLA-B39 in AS and pauciarticular JRA, 1672
Seropositive HTLV-1, in PM, 690
Seropositive RA, T cell receptors in, 1242
Serotypes, Lyme borreliosis and, 565
Serum
albumin, 164, 1092, 1194, 1851
alkaline phosphatase, in quantitative bone scintigraphy in monostotic Paget's disease of bone, 1506
amyloid A, 29, 1447
in amyloidosis, 1851
antibodies, 1418
anti-CAMPATH-1H, human monoclonal antibody CAMPATH- 1H in RA and, 1187
anti-U1 RNA antibodies in connective tissue disease and, 1837
autoantibodies in SSc in twins and, 1845
autoepitopes of 52-kd SS-A/Ro molecule and, 990
autoimmune response to the spliceosome and, 777
in bone marrow transplantation in antiphospholipid syndrome, 115
cartilage matrix protein, in relapsing polychondritis, 294
chondrocytes in aging and development and, 960
C-reactive protein, 1447
cytokines, 211, 601
enteroviral RNA, bacterial DNA and, in juvenile DM, 1513
estradiol, bone turnover and bone mass after, 292
folate, 601
hepatitis, autoimmunity and, 301
HTLV-1 in PM and, 690
human monoclonal antiphospholipid antibody, 1068
hyaluronic acid, in OA, 760
Serum (cont'd)
in JRA, 1735
Mi-2 autoantigen in DM and, 123, 1389
osteocalcin, 902
parvovirus B19 infection, chronic fatigue syndrome and, 638
in RA, 29, 601, 744, 902, 969, 1031, 1046, 1107, 1418, 1447, 1771, 1851
RF, 1771
in SLE, 633, 1055, 1485, 1735
soluble Fas/APO-1 in autoimmune disease and, 1738
soluble Fas/APO-1/CD95 in, 1735
in SSc, 184, 406, 939, 985
Sesamoid ligaments, CPPD synovitis in rabbit OA and, 201
7-D-4 monoclonal antibodies
in detecting biochemical markers of arthritis, 655
glycosaminoglycan epitopes in knee joint fluid after trauma and, 953
70K protein, MHC class II genes, anti-U1 snRNP antibody and, 396
70-kd protein, HRES-1 antibodies and, in SLE and overlap syndromes, 1660
72-kd gelatinase, Arg-Gly-Asp (RGD), IL-1, chondrocyte matrix metalloproteinase synthesis and, 1304
Sexual abuse
childhood, fibromyalgia and, 161, 229, 235
in fibromyalgia, 161, 229, 235
Shared-epitope DRB1 alleles, RA gene and, 1754
Sheath, tendon, joint and connective tissue ultrasonography of, 736
Shigella, in pathogenesis of spondylarthropathies, 1547
Shooting (athletic), knee OA in athletes after, 539
Short Form Geriatric Depression Scale, in RA, 49
Short-term opioid analgesics, guidelines for medical management of OA and, 1535
Sialadenitis in Sjogren's syndrome
autoimmune, in MRL/lpr mice, 1077
focal lymphocytic, 869
Sialoprotein, bone, in RA SF, 82
SIBPAL computer program, T cell receptor β chain genes in RA susceptibility and, 91
Sicca manifestations, cognitive deficit in rheumatic diseases and, 1361
Sickle cell anemia, bone marrow fat in inflammatory response to sickled erythrocytes and, 1349
Sickle cell disease, pseudoseptic inflammatory knee effusion in, 284
Sickled erythrocytes, bone marrow fat and inflammatory response to, 1349
Signal transduction
Arg-Gly-Asp (RGD) peptide, IL-1, chondrocyte matrix metalloproteinase synthesis and, 1304
cytokines, early response genes and, 877
IgG receptors in autoimmune disease and, 306
Silicone implants
breast, scleroderma and, 719
rheumatic disorders and, 721
Single-dose oral MTX, long-term, single-weekly dose, liver biopsy after, in RA, 1194
Single-photon-emission computed tomography, to study cerebral blood flow, pain and, in women with fibromyalgia, 926
Single-strand conformational polymorphism analyses, to study T cell receptor Vβ genes in, in MRL/lpr mice with Sjogren's syndrome, 1077
Single-stranded DNA, human monoclonal antiphospholipid antibody and, 1068
Site-directed mutant DR molecules, p4 peptide pocket binding to DRB1*0401 and, 1644
Sitting, lumbar spinal stenosis and, 1236
6-mercaptopurine, immunosuppressive drugs during pregnancy and, 1722
60-kd heat-shock protein, in pathogenesis of spondylarthropathies, 1547
66/68-joint count, 28-joint count in RA and, 38
Sjogren's syndrome
antibodies to synovial antigens in early RA and, 1418
autoimmune disease induction by microbial pathogens and, 458
cognitive deficit in rheumatic diseases and, 1361
focal lymphocytic sialadenitis in, 867
T cell receptor Vβ genes in, in MRL/lpr mice, 1077
Skeletal hyperostosis, diffuse idiopathic
clinical image, 1345
tracheal stenosis secondary to, 296
Skeleton
maturity of, chondrocytes in aging and development and, 960
monoclonal antibodies in detection of biochemical markers of arthritis and, 655
in osteoporosis in RA, 806
in radiographic hip OA and bone mineral density, 907
Skin
acute posterior multifocal placoid pigment epitheliopathy in JRA and, 446
biopsy, 862, 1157, 1791
cancer, cyclophosphamide in RA and, 1120
cognitive deficit in rheumatic diseases and, 1361
infection, risk factors for septic arthritis in joint disease and, 1819
lesions, 184, 1152, 1161
oral 2-chlorodeoxyadenosine in psoriatic arthritis and, 1604
rash, leflunomide in RA and, 1595
in Raynaud's phenomenon and scleroderma, 1
scleroderma in Tsk2 mouse and, 1791
in SSc, 184, 351, 939
35S-labeled cell lines, autoantibodies in SSc in twins and, 1845
Sleep
cognitive deficit in rheumatic diseases and, 1361
electroencephalography, amitriptyline and, in fibromyalgia, 1211
in SLE, 826, 1475
Slow-acting antirheumatic drugs (SAARD)
draft guidelines for drugs in JRA clinical trials and, 715
guidelines for medical management of OA and, 1535, 1541
IL-10 in RA and, 96
NSAID-induced gastroduodenal injury in children and, 1225
Sm antigen, HeLa cell, MHC class II genes, anti-U1 snRNP antibody and, 396
Small nuclear RNP, anti-U1 antibody, MHC class II genes and, 396
35S-methionine-labeled HEp-2 cell proteins, Mi-2 autoantigen in DM and, 1389
Smoking, NSAID, gastrointestinal tract and, 5
SNF2/RAD 54 helicase family, Mi-2 autoantigen in DM and, 1389
S-nitroso-N-acetyl-penicillamine, nitric oxide and lipoxin
A4 in polymorphonuclear vascular cytotoxicity and, 768
Soccer players, knee OA in, 539
Social factors
in cost and impact of musculoskeletal conditions, 1351
in guidelines for medical management of OA, 1535
work disability in RA and, 1630
Socioeconomic factors, in SLE, 267, 274, 1492
Soft tissue
elastin, collagen degradation and, in SSc, 517
joint and connective tissue ultrasonography in, 736
osteoporosis in RA and, 806
Solid-phase adsorption, nucleosome-restricted antibodies in SLE and, 1485
Solid-phase cardiolipin, cross-reactivity of anticardiolipin autoantibodies with oxidized low-density lipoprotein and, 1382
Soluble adhesion molecules, disease activity in SSc and, 184
Soluble circulating Fcγ receptors, IgG receptors in autoimmune disease and, 306
Soluble cytokines, early response genes and, 877
Soluble Fas/APO-1, in autoimmune disease, 1738
Soluble Fas/APO-1/CD95, in SLE and JRA, 1735
Soluble TNFα receptors, in RA, 151
Somatic involvement, in clenched fist syndrome, 57
Somatostatin, in experimental arthritis, 1687
Sonography
high-frequency, finger tendons in RA and, 786
joint and connective tissue ultrasonography and, 736
Southern blotting, to study T cell receptors in RA, 577
Spanish outcome measures, translation and validation of, 1429
Spectrophotometric assay, to study lipoprotein oxidation and SSc, 1060
Spectroscopy, ultraviolet absorption, to study elastin and collagen degradation in SSc, 517
Spin-spin relaxation, of brain in SLE, 810
Spine
in gout, 139
in juvenile AS, 835
lumbar, 139, 907
lumbar stenosis of, 1236
lumbosacral, impairment of, in walking velocity in elderly, 343
osteoporosis in RA and, 806
prednisone vs chloroquine in RA in elderly in, 334
Spirochetal diseases, Lyme borreliosis and, 565
Spirochete-like organisms, Lyme disease in elderly forester with symptoms of DM and, 1157
Spleen
antibodies to synovial antigens in early RA and, 1418
clodronate-containing liposomes in rat adjuvant arthritis and, 1777
Spliceosome, autoimmune response to, 777
Splinter hemorrhages, in cutaneous PAN associated with Crohn's disease and atrial myxoma, 1161
Spondylarthropathy
IL-10 in RA and, 96
pathogenesis of, 1547
seronegative, HLA-B39 in AS and pauciarticular JRA , 1672
sulfasalazine in, 618
Spondyloepimetaphyseal, spondyloepiphyseal dysplasia, COL2A1 gene mutations in, 999
Spontaneous RF-secreting B cells, endogenous IL-10 and, in RA, 1771
Sports medicine
joint and connective tissue ultrasonography in, 736
knee OA in atheletes, 539
Sprague-Dawley rats, radiographic changes in adjuvant arthritis in, 129
Squatting work, knee OA in athletes and, 539
35S-sulfate, proteoglycan synthesis in canine OA and, 525
SS-A/Ro molecule, 52-kd, autoepitopes of, 990
Stab wounds, tenidap in experimental canine OA and, 1290
Stanford Arthritis Self-Management Program, Arthritis Knowledge Questionnaire and, 590
Staphylococcus aureus, septicemia, spinal involvement in gout and, 139
STAT proteins, cytokines, early response genes and, 877
Stellate cells, complement in RA and, 492
Stenosis
lumbar spinal, 1236
tracheal, secondary to DISH, 296
Steroid drugs
hormone replacement, bone metabolism and, in postmenopausal RA, 902
MTX in Cogan's syndrome and, 1348
Stevens, Mary Betty, obituary, 444
Stiffness
MRI, PET and, in RA, 819
stromelysin degradation of cartilage and, 173, 1678
Stifle joint
stromelysin-cleaved rabbit aggrecan and, 1400
stromelysin degradation of cartilage and, 1678
tenidap in experimental canine OA and, 1290
Still's disease, acute posterior multifocal placoid pigment epitheliopathy in, 446
Stress fractures, in RA, 1025
Stress management, in clinical outcomes in RA, 1807
Stress maneuver, tibiofemoral, directed knee examination, cartilage abnormalities and, 917
Stromelysin
cartilage degradation 173, 1678
metalloproteinase and, 969, 1031, 1304
1, in RA, 969, 1031
in rabbit aggrecan, 1400
Study of Osteoporotic Fractures, radiographic hip OA, bone mineral density and, 907
Subchondral sclerosis, radiographic hip OA, bone mineral density and, 907
Subcortical brain region, cognitive deficit in rheumatic diseases and, 1361
Substance P, calcitonin gene-related peptide and, in rat adjuvant arthritis, 699
Sucralfate, NSAID, gastrointestinal tract and, 5
Sulfasalazine
in spondylarthropathy, 618
toxic epidermal necrolysis after, in psoriatic arthritis, 573
Sulfate
chondroitin, in knee joint fluid after trauma, 953
keratan, 660, 953, 1031
in OA, 78, 525
Sun exposure and sun protection, Ro and La antigens in human skin and, 1271
Superantigens, autoimmune disease induction by microbial pathogens and, 458
Superoxides
anion production, nitric oxide and lipoxin A4 in polymorphonuclear vascular cytotoxicity and, 768
dismutase, TGFβ1 in hyaluronan synthesis in synovial lining cells, 669
peripheral blood neutrophils in Behcet's disease and, 426
Support groups, prevalence and incidence of SLE in Birmingham, England and, 551
Suppressor cells, in AIDS in active RA, 1701
Supraspinatus tendon, in complete rotator cuff tear, 288
Surface antigens, Chlamydia trachomatis in synovial membranes and, 1410
Surface radioactivity, synovitis, protein clearance and, 1085
Surgery
decompression procedures in carpal tunnel syndrome due to T cell lymphomas, 1707
hip, infection, onset of giant cell arteritis and, 374
hypothalamic-pituitary-adrenal effects of NSAID and, 723
joint replacement, in end-stage OA, cardiovascular fitness and, 799
in OA, 201, 448, 760, 1541
in RA, 642, 1315
risk factors for septic arthritis in joint disease and, 1819
Survival
after corticosteroids, pulse cyclophosphamide and plasma exchange in polyarteritis nodosa and Churg-Strauss syndrome, 1638
immunosuppressive drugs during pregnancy and, 1722
in polymyalgia rheumatica, 369
in RA, 326, 1120, 1618
Survival (cont'd)
of rheumatology subspecialty, 451
in SLE, 274, 1492
Swelling
acute cerebral, spin-spin relaxation of brain in SLE and, 810
in clenched fist syndrome, 57
joint, 38, 601, 669, 727, 1093, 1177, 1568, 1581, 1687
nitric oxide synthase in articular chondrocytes in pathogenesis of, 1529
in pseudoseptic inflammatory knee effusion in sickle cell disease, 284
self-administered RADAI in epidemiology and, 795
somatostatin in experimental arthritis and, 1687
stromelysin degradation of cartilage and, 173
type II collagen in antigen-induced arthritis and, 1092
Swiss mice, CD-1, enterviral RNA and bacterial DNA in juvenile DM in, 1513
Symmetric polyarthritis, AIDS in active RA and, 1701
Symmetric sensory or sensorimotor neuropathy, peripheral neuropathy with necrotizing vasculitis in RA and, 1618
Syncytial virus, enteroviral RNA bacterial DNA and, in juvenile DM, 1513
Synergism, Arg-Gly-Asp (RGD), IL-1, chondrocyte matrix metalloproteinase synthesis and, 1304
Synovial antigens, antibodies to, in early RA, 1418
Synovial biopsy
anti-CD4 monoclonal antibody in early RA and, 1457
in hydatid disease in chronic monarthritis, 1338
MRI in rheumatoid synovitis and, 1610
Synovial cartilage, CPPD synovitis in rabbit OA and, 201
Synovial cells
CD4, 1457
cytokines, early response genes and, 877
fibroblast-like, EDA-containing fibronectin in, 678
nuclear factor κB in rheumatoid synovium and, 1762
in RA, 485, 577, 976, 1457, 1762
T, 577, 1547
TGFβ1 in hyaluronan synthesis in, 669
Synovial deoxyglucose metabolism, MRI, PET and, in RA, 819
Synovial fibroblast adhesion, rheumatoid, to human articular cartilage, 1694
Synovial fluid (SF)
Arg-Gly-Asp (RGD), IL-1, chondrocyte matrix metalloproteinase synthesis and, 1304
Chlamydia DNA and, in reactive arthritis, 1005
Chlamydia trachomatis in synovial membranes and, 1410
cytokines, early response genes and, 877
glycosaminoglycan epitopes in knee joint fluid after trauma and, 953
nitric oxide synthase in articular chondrocytes in pathogenesis of swelling and, 1529
in pathogenesis of spondylarthropathies, 1547
pseudoseptic inflammatory knee effusion in sickle cell disease and, 284
in RA, 82, 96, 151, 577, 649, 678, 969, 1863
scintigraphic abnormalities, bone turnover and, in OA, 78
stromelysin degradation of cartilage and, 1678
synovitis, protein clearance and, 1085
T cells, 1547
Synovial hemangioma, localized, 559
Synovial inflammation
acute, MRI in rheumatoid synovitis and, 1610
synovitis, protein clearance and, 1085
tenidap in experimental canine OA and, 1290
Synovial lining
cells, 669, 1762
nuclear factor κB in rheumatoid synovium and, 1762
in RA, 492, 678, 976, 1762
Synovial lysates, antibodies to synovial antigens in early RA and, 1418
Synovial membrane
Chlamydia trachomatis in, 1410
clodronate-containing liposomes in rat adjuvant arthritis and, 1777
histologic findings in sacroiliitis in AS and, 499
MRI in rheumatoid synovitis and, 1610
in pathogenesis of spondylarthropathies, 1547
in RA, 750, 1346
synovial T cells, IL-10 and, 946
tenidap in experimental canine OA and, 1290
Synovial monocytes, IL-6 in RA and, 1046
Synovial tissue
CAMPATH 1-H and, 254
cathepsin, collagenase and, 976
cytokines, early response genes and, 877
nuclear factor κB in rheumatoid synovium and, 1762
in OA, 976
in RA, 151, 477, 577, 750, 976, 1046, 1242, 1418, 1457, 1762
Synovial volume, MRI, PET and, in RA, 819
Synoviocytes, in RA, apoptosis and functional Fas antigen in, 485
Synovitis
anti-U1 RNA antibodies in connective tissue disease and, 1837
CPPD-induced, in rabbit OA, 201
``detritic,'' 1315
granulomatous, hydatid disease in chronic monarthritis and, 1338
knee, MRI in, 1610
low-grade, protein clearance and, 1085
in RA, 254, 1315, 1418
rheumatoid, 151, 1610
Synovium
autoimmune disease induction by microbial pathogens and, 458
CPPD synovitis in rabbit OA and, 201
Klebsiella pneumoniae-reactive T cells in AS and, 1277
in RA, 477, 485, 492, 678, 750, 819, 1046, 1242
rheumatoid, 477, 485, 1762
substance P and calcitonin gene-related peptide in, in rat adjuvant arthritis, 699
Synthase, nitric oxide, in articular chondrocytes in pathogenesis of swelling, 1529
Synthetic matrix metalloproteinase inhibitor, N-carboxyalkyl, L-696,418, stromelysin degradation of cartilage and, 1678
Synthetic peptides
HRES-1 antibodies and, in SLE and overlap syndromes, 1660
Yersinia enterocolitica, adhesin YadA, on collagen and, 1283
Systemic autoimmunity, understanding of, 301
Systemic glucocorticoids, low-dose, MRI, PET and, in RA, 819
Systemic inflammation, metalloproteinases in RA and, 1031
Systemic JRA
acute posterior multifocal placoid pigment epitheliopathy in, 446
cytokines in, 211
Systemic lupus erythematosus (SLE)
Activity Measure (SLAM), socioeconomic factors, morbidity and, 267
anti-apolipoprotein A1 in, 1655
antineutrophil cytoplasmic antibodies in, 633
autoimmune response to the spliceosome in, 777
bullous rash and brown urine after hydroxychloroquine in, 440
carbohydrate content of immune complexes in RA and, 744
cognitive deficit in rheumatic diseases and, 1361
cross-reactivity of anticardiolipin autoantibodies with oxidized low-density lipoprotein and, 1382
cutaneous LE exacerbation from ultraviolet emissions from a photocopier, 1152
cytolytic activity of polyclonal T cells in, 506
dehydroepiandrosterone in, 1826
disease activity in, socioeconmic factors, morbidity and, 267
Systemic lupus erythematosus (SLE) (cont'd)
Disease Activity Index (SLEDAI) in, 1826
DNA binding of IgM[gl] anti-DNA antibody and, 389
fatal pulmonary vasculitis in pregnancy in, 710
fatigue in, 826
Fc receptor IIa polymorphism and renal disease in, 1832
fibromyalgia in, 872
geographic clusters of, 1564
HLA type in, 259
HRES-1 antibodies in, 1660
human monoclonal antiphospholipid antibody in, 1068
IgG anti-DNA antibody T14, DNA binding of IgM[gl] anti-DNA antibodies and, 389
IgG receptors in, 306
IgM deficiency in, 1713
IgM nephritogenic antibodies, DNA binding of IgM[gl] anti-DNA antibodies and, 389
IL-1 receptor antagonist in, 1055
mannose-binding protein in, 110, 1713
measuring relevant change in clinical trials in, 1027
Mi-2 autoantigen in DM and, 1389
mortality in, 1492
nucleosome-restricted antibodies in, 1485
patient subsets in, 1475
polyclonal T cells in, 506
pregnancy in, 710, 1722
prevalence and incidence of, 551, 1260
socioeconomic predictors of morbidity in, 267
soluble Fas/APO-1 in autoimmune disease and, 1738
spin-spin relaxation of brain in, 810
survival in, 274
T cells in, 506
Systemic N-carboxyalkyl synthetic matrix metalloproteinase inhibitor, L-696,418, stromelysin degradation of cartilage and, 1678
Systemic sclerosis (SSc)
See also scleroderma
antihistone antibodies and pulmonary fibrosis in, 1024
autoantibodies in, 985, 1845
cutaneous, 351, 985
diffuse, 351
eosinophil major basic protein in, 939
E-selectin in, 406
guidelines for clinical trials in, 351
HLA type and, 259
limited, 985
lipoprotein oxidation and, 1060
pulmonary dysfunction in, cyclophosphamide in, 147
Raynaud's phenomenon and, 1
soluble adhesion molecules in disease activity in, 184
in Tsk2 mouse, 1791
Systemic sclerosis-like illness, guidelines for clinical trials in SSc and, 351
Systolic blood pressure, racial factors in gout and, 628